Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with others

1 Jan 2021

Abstract excerpt

Several large clinical trials are underway to discover therapies to delay or prevent the onset of dementia caused by Alzheimer's disease (AD). A common feature of these trials is that they are testing therapies in people who do not yet have changes in memory or thinking-that is, who are cognitively unimpaired-but who have a biologically defined risk of developing dementia caused by AD. When these trials...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to Ethics in Clinical Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34040780
DOI: 10.1093/jlb/lsab004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with othersPMID 34040780Read ↗

Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease ContinuumSemantic proximity Read ↗

Considerations regarding a diagnosis of Alzheimer’s Disease before dementia: a systematic reviewSemantic proximity Read ↗

Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II).Semantic proximity Read ↗

A Multidisciplinary Perspective on Research Participation in the Era of Post-Amyloid Disclosure and Disease-Modifying TherapiesSemantic proximity Read ↗

To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk.Semantic proximity Read ↗

Attitudes towards Personal Genomics and Sharing of Genetic Data among Older Swiss Adults: A Qualitative StudySemantic proximity Read ↗

Public perceptions of presymptomatic testing for Alzheimer disease.Semantic proximity Read ↗

A survey study of Alzheimer’s stigma among Black adults: intersectionality of Black identity and biomarker diagnosisSemantic proximity Read ↗

"It seems enormously valuable to me." Perspectives of Dutch (potential) carriers of genetic FTD on onset-predictive biomarker testing.Semantic proximity Read ↗

The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm?Semantic proximity Read ↗

Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research contextSemantic proximity Read ↗

Participant attitudes toward returning individual results from CADASIL researchSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.